Dexmedetomidine/fentanyl

Dexmedetomidine/fentanyl Reactions 1680, p118 - 2 Dec 2017 Mild respiratory depression, opioid withdrawal syndrome and resistance to dexmedetomidine: case report A 61-year-old woman developed respiratory depression during treatment with fentanyl and opioid withdrawal syndrome following withdrawal of fentanyl. Additionally, she developed resistance to dexmedetomidine. The woman, who had a history of Grave’s disease, was hospitalized for deep cervical abscess due to α-Streptococcus spp. She started receiving treatment with antibiotics, analgesic fentanyl and sedative dexmedetomidine [route and duration of treatment to reaction onset not stated] targeting the Richmond agitation-sedation scale from 0 to -2. She also received propofol if required. She underwent neck drainage surgery for descending necrotising mediastinitis on hospital day 4 and mediastinal drainage on day 9, for an enlarged mediastinal abscess despite conservative therapy. Afterwards, her deep cervical abscess and haemodynamic and respiratory status improved; however, marked laryngeal oedema hindered extubation. Due to persistent laryngeal oedema she continued dexmedetomidine and fentanyl for management of mechanical ventilation. After reduction of laryngeal oedema on day 30, she developed mild respiratory depression and therapy with fentanyl was discontinued. Her respiratory status improved after administration of naloxone and subsequently extubation was carried out. Her total fentanyl dose was 1.6 mg/kg for 30 days and her treatment with dexmedetomidine 0.3 µg/kg/hour was continued after extubation. She experienced progressive rise in heart rate, respiratory rate, body temperature and blood pressure several hours after extubation. Subsequently, she was diagnosed with opioid withdrawal syndrome. The woman’s dose of dexmedetomidine was increased to 0.8 µg/kg/hour; but, no improvement in her symptoms of opioid withdrawal syndrome (OWS) was noted. She was treated with diltiazem infusion; however, her symptoms persisted even after maximal administration of diltiazem. Therefore on day 32, she was additionally treated with nifedipine administered through a nasogastric tube. Even though she developed transient hypotension, her OWS symptoms, including tachycardia, tachypnea, hyperthermia and hypertension, were resolved without recurrence. On th 38 day, she was discharged from the ICU and being followed- up for her wounds at the hospital. Author comment: "First, fentanyl administration was terminated, and because of mild respiratory depression due to fentanyl we, administered 0.1mg naloxone." "In our case, although dexmedetomidine was given prior to extubation and after development of opioid withdrawal syndrome, it was unable to resolve opioid withdrawal syndrome symptoms. It is possible that the patient developed resistance to dexmedetomidine because of prolonged treatment (for 3 weeks)." Shimatani T, et al. Calcium channel blocker attenuated opioid withdrawal syndrome. Acute Medicine and Surgery 2: 114-116, No. 2, Apr 2015. Available from: URL: http://doi.org/10.1002/ams2.72 - Japan 803284720 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Dexmedetomidine/fentanyl

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/dexmedetomidine-fentanyl-n0lEhVOfuQ
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39049-7
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p118 - 2 Dec 2017 Mild respiratory depression, opioid withdrawal syndrome and resistance to dexmedetomidine: case report A 61-year-old woman developed respiratory depression during treatment with fentanyl and opioid withdrawal syndrome following withdrawal of fentanyl. Additionally, she developed resistance to dexmedetomidine. The woman, who had a history of Grave’s disease, was hospitalized for deep cervical abscess due to α-Streptococcus spp. She started receiving treatment with antibiotics, analgesic fentanyl and sedative dexmedetomidine [route and duration of treatment to reaction onset not stated] targeting the Richmond agitation-sedation scale from 0 to -2. She also received propofol if required. She underwent neck drainage surgery for descending necrotising mediastinitis on hospital day 4 and mediastinal drainage on day 9, for an enlarged mediastinal abscess despite conservative therapy. Afterwards, her deep cervical abscess and haemodynamic and respiratory status improved; however, marked laryngeal oedema hindered extubation. Due to persistent laryngeal oedema she continued dexmedetomidine and fentanyl for management of mechanical ventilation. After reduction of laryngeal oedema on day 30, she developed mild respiratory depression and therapy with fentanyl was discontinued. Her respiratory status improved after administration of naloxone and subsequently extubation was carried out. Her total fentanyl dose was 1.6 mg/kg for 30 days and her treatment with dexmedetomidine 0.3 µg/kg/hour was continued after extubation. She experienced progressive rise in heart rate, respiratory rate, body temperature and blood pressure several hours after extubation. Subsequently, she was diagnosed with opioid withdrawal syndrome. The woman’s dose of dexmedetomidine was increased to 0.8 µg/kg/hour; but, no improvement in her symptoms of opioid withdrawal syndrome (OWS) was noted. She was treated with diltiazem infusion; however, her symptoms persisted even after maximal administration of diltiazem. Therefore on day 32, she was additionally treated with nifedipine administered through a nasogastric tube. Even though she developed transient hypotension, her OWS symptoms, including tachycardia, tachypnea, hyperthermia and hypertension, were resolved without recurrence. On th 38 day, she was discharged from the ICU and being followed- up for her wounds at the hospital. Author comment: "First, fentanyl administration was terminated, and because of mild respiratory depression due to fentanyl we, administered 0.1mg naloxone." "In our case, although dexmedetomidine was given prior to extubation and after development of opioid withdrawal syndrome, it was unable to resolve opioid withdrawal syndrome symptoms. It is possible that the patient developed resistance to dexmedetomidine because of prolonged treatment (for 3 weeks)." Shimatani T, et al. Calcium channel blocker attenuated opioid withdrawal syndrome. Acute Medicine and Surgery 2: 114-116, No. 2, Apr 2015. Available from: URL: http://doi.org/10.1002/ams2.72 - Japan 803284720 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off